CDTX Stock Risk & Deep Value Analysis
Cidara Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on CDTX
We analyzed Cidara Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CDTX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈CDTX Performance Overview3yr weekly
Unlock CDTX Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
CDTX Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Cidara Therapeutics Inc (CDTX)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
mid
Market Cap
$3.43B
CDTX Deep Value Analysis
CDTX Red Flags & Warning Signs
Premium- ⚠
Lower-than-expected REZZAYO® commercial sales ramp or increased competition.
- ⚠
Negative or inconclusive clinical trial results for Cloudbreak platform candidates.
- ⚠
Termination or renegotiation of key partnerships (e.g., Janssen).
- ⚠
Significant dilution through equity raises to fund R&D.
Unlock CDTX Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
CDTX Financial Health Metrics
Market Cap
$3.43B
CDTX Competitive Moat Analysis
PremiumMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is primarily derived from Cidara's intellectual property protecting Rezafungin and the Cloudbreak platform. As Cloudbreak advances clinically and secures additional partnerships, its unique approach to antiviral discovery strengthens the moat by making it harder for competitors to replicate its broad-spectrum potential without similar foundational technology or partnerships.
CDTX Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
CDTX Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated early March 2026): Focus on Rezafungin sales growth and cash burn.
- •Update on REZZAYO® commercial expansion or new indication filings (Q1-Q2 2026).
- •IND filing or preclinical data presentation for a new Cloudbreak program (H1 2026).
Medium-Term (6-18 months)
- •Phase 1 clinical trial initiation/data for a lead Cloudbreak antiviral candidate (H2 2026 - H1 2027).
- •New strategic partnership announcement for Cloudbreak platform or specific antiviral target (2027).
- •Further expansion of REZZAYO® into international markets or additional indications (2027).
Long-Term (18+ months)
- •Cloudbreak platform's potential to deliver a universal flu vaccine or broad-spectrum antivirals, disrupting infectious disease treatment paradigms (2028+).
- •Establishment as a leading player in novel antifungal and antiviral therapies.
- •Acquisition by a larger pharmaceutical company seeking infectious disease platform technology.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
CDTX Bull Case: What Could Go Right
- ✓
Acceleration in REZZAYO® net product sales and positive updates on market penetration.
- ✓
Announcements of new Cloudbreak development candidates entering clinical trials or securing new collaboration agreements.
- ✓
Positive preclinical or early clinical data readout for any Cloudbreak antiviral program.
Bull Case Analysis
See what could go right with Premium
Never miss a move on CDTX
Create a free account to set price alerts and get notified on Telegram when CDTX hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Cidara Therapeutics Inc (CDTX)?
As of February 16, 2026, Cidara Therapeutics Inc has a DVR Score of 7.0 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Cidara Therapeutics Inc?
Cidara Therapeutics Inc's market capitalization is approximately $3.4B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Cidara Therapeutics Inc use?
CDTX is the ticker symbol for Cidara Therapeutics Inc. The company trades on the NCM.
What is the risk level for CDTX stock?
Our analysis rates Cidara Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the CDTX DVR analysis updated?
Our AI-powered analysis of Cidara Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on February 16, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.